Summary: Orgenesis reports on expanding clinical initiatives, partnerships, and financial results for Q3 2024

From GlobeNewswire: 2024-11-13 08:00:00

Orgenesis Inc. provided a business update for the third quarter of 2024, focusing on expanding clinical initiatives and global partnerships to bring innovative cell and gene therapies to patients worldwide. A recent study showed their CD19 CAR-T therapy, ORG-101, achieved high response rates with lower side effects, validating their decentralized approach. They are initiating a Phase 1/2 multicenter clinical study in Greece.

The company also offers a unique partnership to hospitals and research centers for swift and cost-efficient capacity building to provide cell and gene therapies. Their strategic joint venture with Harley Street Healthcare Group aims to introduce longevity and wellness services in key markets like the UK, UAE, and Canada. This partnership combines cell and gene therapy innovations with established healthcare networks for impactful innovations.

In addition to their business update, Orgenesis released their financial results for the third quarter of 2024, showing total assets of $29,687, with current assets at $2,519 and non-current assets at $27,168. Liabilities totaled $53,615, with current liabilities at $36,049 and long-term liabilities at $17,566. The company’s capital deficiency was reported at $23,928, with a total comprehensive loss of $9,783 for the quarter.

These updates reflect Orgenesis’ commitment to advancing cell and gene therapies through their decentralized approach, clinical studies, and strategic partnerships. Their financial results demonstrate the company’s assets, liabilities, and capital position, providing transparency to investors and stakeholders. Orgenesis continues to drive healthcare innovations for improved patient access and outcomes worldwide.



Read more at GlobeNewswire:: Orgenesis Provides Third Quarter 2024 Business Update